The epidermal growth factor receptor (EGFR) is overexpressed in a variety of human
epithelial tumors, often as a consequence of gene amplification. Tumors with EGFR gene …

Aberrant epidermal growth factor receptor (EGFR) signaling is common in cancer. Increased
expression of wild type and mutant EGFR is a widespread feature of diverse types of cancer …

Glioblastomas may develop de novo (primary glioblastomas) or through progression from
low-grade or anaplastic astrocytomas (secondary glioblastomas). These subtypes of …

Deregulation of signaling by the epidermal growth factor receptor (EGFR) is common in
human malignancy progression. One mutant EGFR (variously named ΔEGFR, de2-7 EGFR …

Glioblastoma multiforme (GBM) is the most common brain tumour and has the worst
prognosis. Epidermal growth factor receptor (EGFR) gene amplification, mutation and re …

The epidermal growth factor receptor (EGFR) is a primary contributor to glioblastoma (GBM)
initiation and progression. Here, we examine how EGFR and key downstream signaling …

Constitutive activation of the EGFR is common in cancer due to EGFR wild-type (EGFRwt)
overexpression or the presence of mutant EGFR. Signaling by constitutively active NSCLC …

The epidermal growth factor receptor (EGFR) is overexpressed and/or constitutively
activated in a variety of human malignancies. Detection of increased expression levels of …

Alterations of the epidermal growth factor receptor (EGFR) gene occur frequently in human
malignant gliomas. The most common of these is deletion of exons 2–7, resulting in …

In the year 2000, an estimated 1220100 new cases of invasive cancer will be diagnosed in
the United States, and about 552 200 people are expected to die of it (Greenlee et al. 2000) …